HNRNPH1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, high hnRNPH1 expression correlates with disease progression and imatinib resistance via the negative regulation of PTPN6, maintenance of PI3K/AKT pathway activation, and the positive regulation of BCR-ABL expression.